DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned a consensus rating of “Moderate Buy” from the twenty-seven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, twenty-one have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $88.7083.

A number of brokerages recently issued reports on DXCM. Truist Financial set a $93.00 price target on DexCom and gave the company a “buy” rating in a report on Friday, July 31st. Citigroup reiterated a “buy” rating and issued a $88.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, July 31st. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Weiss Ratings raised DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Finally, Royal Bank Of Canada upped their target price on DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, July 31st.

DexCom Price Performance

Shares of DexCom stock opened at $90.82 on Monday. The firm has a market cap of $34.27 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 1.53 and a beta of 1.41. DexCom has a 12-month low of $54.11 and a 12-month high of $92.59. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The company’s fifty day simple moving average is $79.21 and its two-hundred day simple moving average is $71.61.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.48 earnings per share. As a group, equities analysts expect that DexCom will post 2.64 EPS for the current year.

Insiders Place Their Bets

In related news, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the sale, the executive vice president owned 100,361 shares of the company’s stock, valued at $7,326,353. This trade represents a 4.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 75,600 shares of company stock worth $5,673,342. Company insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Corient Private Wealth LP grew its stake in DexCom by 3.1% in the second quarter. Corient Private Wealth LP now owns 130,738 shares of the medical device company’s stock worth $8,805,000 after purchasing an additional 3,986 shares during the period. Brown Financial Advisors lifted its position in DexCom by 13.7% during the second quarter. Brown Financial Advisors now owns 17,222 shares of the medical device company’s stock valued at $1,160,000 after buying an additional 2,080 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of DexCom during the 2nd quarter valued at $36,285,000. California State Teachers Retirement System boosted its holdings in shares of DexCom by 6,567.7% during the 2nd quarter. California State Teachers Retirement System now owns 39,176,552 shares of the medical device company’s stock valued at $2,638,541,000 after buying an additional 38,588,991 shares in the last quarter. Finally, HB Wealth Management LLC grew its position in shares of DexCom by 16.5% in the 2nd quarter. HB Wealth Management LLC now owns 8,707 shares of the medical device company’s stock worth $586,000 after buying an additional 1,233 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.